Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + Bevacizumab in Cisplatin-ineligible Urothelial Cancer
NCT03272217Phase 2Terminated
- Start
- Sep 2017
- Primary completion
- May 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab and bevacizumab in urothelial carcinoma (UC). Primary endpoint: Overall Survival Rate at 1 year. Started Sep 2017; status: terminated.
02
Drugs
atezolizumabbevacizumab
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03272217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03272217.